Rani Therapeutics Holdings, Inc. (RANI): Price and Financial Metrics
GET POWR RATINGS... FREE!
RANI Stock Price Chart Interactive Chart >
RANI Price/Volume Stats
|Current price||$11.32||52-week high||$36.27|
|Prev. close||$10.77||52-week low||$9.24|
|Day high||$12.00||Avg. volume||41,049|
|50-day MA||$12.45||Dividend yield||N/A|
|200-day MA||$17.99||Market Cap||556.49M|
Rani Therapeutics Holdings, Inc. (RANI) Company Bio
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; RT-103, a glucagon-like peptide-1 mimetic to treat type 2 diabetes; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was founded in 2012 and is headquartered in San Jose, California.
Most Popular Stories View All
RANI Latest News Stream
|Loading, please wait...|
RANI Latest Social Stream
View Full RANI Social Stream
Latest RANI News From Around the Web
Below are the latest news stories about Rani Therapeutics Holdings Inc that investors may wish to consider to help them evaluate RANI as an investment opportunity.
Rani Therapeutics Unveils High-Capacity RaniPill™ Device For Oral Delivery of Biologics; Reports Preliminary 2021 Consolidated Financial Results
- Preclinical data demonstrates new RaniPill™ HC (High Capacity) delivered 500%-plus higher payloads than current RaniPill™ capsule - - Up to 20mg payload has the potential to unlock more than 50 additional biologics for internal development or partnership - - Company announces preliminary consolidated financial results for the fourth quarter and year ended December 31, 2021 - SAN JOSE, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Na
Gainers: Weidai (WEI) +79%.Rani Therapeutics Holdings (RANI) +33%.Stride LRN +29%.Exela Technologies XELA +26%.Huadi International (HUDI) +21%.Koss (KOSS) +20%.Sierra (SRRA)
Biotech investors still like BioCryst, Protagonist, Prometheus Biosciences, Rani, and Emergent BioSolutions. All sported recent double-digit gains despite the sector slump.
SAN JOSE, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delivery of biologics, today announced the appointment of Lisa Rometty to its Board of Directors. Ms. Rometty brings significant global commercial leadership experience across a spectrum of start-ups to mature businesses in medical device, technology and pharmaceuticals. “In our effort to pioneer the fiel
Rani Therapeutics (NASDAQ:RANI) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, institutional ownership, earnings, risk and profitability. Analyst Recommendations This is a breakdown of current ratings and recommmendations for Rani Therapeutics and Soligenix, […]
RANI Price Returns